[Metabolomics] Darren Creek - Centenary Institute Tuesday Seminar August 29th

[Ben Crossett]

Hi Folks,

Like busses, you wait ages and then three turn up at once!

Next Tuesday we have another metabolomics talk:

12.00pm to 1.00pm
Tuesday 29th August, 2017

Dr Darren Creek
Senior Lecturer, (Career Development Fellow)
Monash Institute of Pharmaceutical Sciences

"Discovering Mechanisms of Drug Action and Resistance with Metabolomics"

The Centenary Institute
Lecture Theatre, Level 6,
Building 93, Royal Prince Alfred Hospital Grounds

Lunch will be provided for attendees following the seminar.

Darren will be around most of the day, if you would like to meet up with him contact:  Anthony Don [mailto:a.don at centenary.org.au]


About the speaker:

Dr Darren Creek is a Senior Lecturer, NHMRC Career Development Fellow and head of the pharmaceutical metabolomics laboratory at the Monash Institute of Pharmaceutical Sciences. He completed his PhD at Monash University in 2007, and performed post-doctoral research in Uganda, Scotland and Australia working on antimalarial drug discovery and clinical trials, before focusing on metabolomics studies of tropical parasites.He developed several novel analytical methods and software tools for the metabolomics  eld, and discovered novel pathways and drug mechanisms in protozoan parasites. Dr Creek’s laboratory currently uses metabolomics and proteomics to understand mechanisms of drug action and resistance for cancer and infectious diseases, with a major focus on African trypanosomiasis and malaria. Darren continues to develop novel metabolomics methods to advance the  eld and is a Director of the international Metabolomics Society.

About the seminar:

Drug resistance poses a major threat to the management of infectious diseases, and new drugs are urgently required for many common infections.Unfortunately, the development of new drugs is often hampered by a lack of knowledge regarding the mechanisms of action and resistance of existing drugs,and of new lead compounds. Recent advances in post-genomic technologies, including metabolomics and proteomics, provide an opportunity for unbiased analysis of the impact of drug treatment on cellular biochemistry, allowing discovery of previously unanticipated mechanisms of drug action and resistance.
We have used these technologies to discover the mode of action of over 100 compounds that target the causative agents of malaria and African trypanosomiasis. Furthermore, multi-omic analysis of malaria parasites resistant to the  rst-, and last-line antimalarials, the artemisinins, revealed depleted levels of a key biomarker protein, and differential regulation of haemoglobin digestion and glutathione synthesis. These  ndings provide opportunities for clinical translation of new biomarkers of drug resistance, and provide direct evidence of the resistance mechanisms which may be exploited to enhance the activity of
these important medicines.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mailman.sydney.edu.au/pipermail/metabolomics/attachments/20170822/70728863/attachment.html>